Concepedia

Magnus Bloe

MB

Statistics

Publications

1

Citations

20

H-Index

1

Active since

2018

Affiliations

National University Cancer Institute, Singapore(Current)

Magnus Bloe is an author at National University Cancer Institute, Singapore specializing in innate antitumor immunity, immunology, and cancer-associated macrophages.

Publications per year

2018–2018

1

Publications

1

Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung.

Murray Yule, Kjersti Davidsen, Magnus Bloe et al. · Journal of Clinical Oncology · 2018 · 20 citations

, , +17

1–1 of 1